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ABSTRACT
Calciphylaxis is a rare condition characterized by the emergence of non-healing skin ulcers secondary to arterial calcification and thrombosis, 
typically diagnosed in patients with end-stage kidney disease (ESKD). When it develops in patients without ESKD, it is called non-uremic 
calciphylaxis (NUC). The latter is an even rarer diagnosis with an uncertain pathophysiology and a high mortality rate (52%), mainly due to 
sepsis (50%). Cutaneous biopsy is diagnostic. Therapeutic measures recommended for NUC are limited to wound debridement, analgesia, 
and control of infection and risk factors. Other therapeutic options exist but with a low level of evidence. We present the case of a 78-year-
old woman with NUC in her lower limbs who died of sepsis. NUC is a therapeutic challenge lacking efficient strategies.
LEARNING POINTS
• Calciphylaxis in the absence of end-stage kidney disease is called non-uremic calciphylaxis (NUC).
• This disease is a diagnostic and therapeutic challenge.
• As therapeutic strategies for NUC mainly derive from those for uremic calciphylaxis, more efficient therapeutic measures and evidence-
based recommendations are needed.
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INTRODUCTION
Calciphylaxis is a rare disease characterized by arterial and arteriole calcification, soft tissue calcification, and thrombosis, resulting in 
ischaemia and skin necrosis[1]. It has a predilection for the lower extremities and areas rich in adipose tissue, although systemic involvement 
(internal organs or muscles) has also been described[1,2]. It is mainly diagnosed in patients with end-stage kidney disease (ESKD) on 
haemodialysis (HD). In this population, the reported incidence of calciphylaxis is 1%, with a prevalence of 4% and 1-year mortality of 45–
80% [1–3]. Calciphylaxis in the absence of ESKD is called non-uremic calciphylaxis (NUC). In one systematic review on NUC which included 36 
cases, the mortality rate was 52% and sepsis was responsible for 50% of deaths, most of them occurring 2 weeks to 1 year after diagnosis[2]. 
A common aetiology for these cases has not been described, although several risk factors and causative agents of NUC have been suggested 
(Table 1) [1,2,4,5]. This is probably related to its pathogenesis. Calciphylaxis is characterized by an insidious asymptomatic medial arteriolar 
calcification, resulting in clinical manifestations when vascular thrombosis occurs. Vascular calcification results from active cellular 
processes involved in biomineralization and the NFkB pathway, being regulated by several factors. Prothrombotic factors are additionally 
involved in the acute development of vascular occlusion[6].
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The diagnosis of NUC requires a high level of suspicion and depends on the identification of the typical clinical features in the presence of 
risk factors and related conditions, while excluding clinical mimics (Table 2)[1,2,4,5]. It usually presents as a painful skin lesion with a livedoid 
pattern progressing to necrosis, frequently with a black stellate eschar and surrounding purpura that heals poorly and frequently becomes 
infected. A cutaneous biopsy is crucial to the diagnosis as findings that include tunica media calcification, fibrointimal hyperplasia of small 
dermal and subcutaneous arteries and arterioles with thrombosis, cutaneous ischaemia and panniculitis are pathognomonic[1–4].
Therapeutic strategies for NUC mainly derive from those for uremic calciphylaxis. Possible triggers of occlusion and factors involved in the 
mineralization process should be identified and treated. Careful surgical or chemical debridement of the lesions, to remove eschar, bacterial 
biofilms and inflamed adipose tissue, is recommended[1–3]. Analgesia should be optimized[1,2], and prompt treatment of sepsis is mandatory. 
Sodium thiosulfate (STS) has been gaining interest due to some successful outcomes, but most reports are on uremic calciphylaxis and 
this is as yet an off-label indication[1,2,7]. Antioxidation, vasodilation and chelation are the mechanisms thought to be responsible for its 
therapeutic action in calciphylaxis[8]. An ongoing clinical trial is evaluating the clinical efficacy of STS in uremic calciphylaxis[9] and its results 
could support a new labelled indication. Other reported therapeutic alternatives are also associated with better outcomes, but most of 
the evidence is inferred from uremic calciphylaxis case reports and case series. These comprise hyperbaric oxygen therapy (HOT) [1,4,10], 
lanthanum carbonate[11], statins[12], bisphosphonates[13], cinacalcet and sevelamer[14]. In selected cases, tissue plasminogen activator therapy 
to address the thrombotic component of the disease may be beneficial[15]. The most recommended strategy is to combine treatments to 
address both vascular calcification and thrombosis, and taking account of the metabolic and coagulation status of each patient.
Table 1. Non-uremic calciphylaxis-associated factors and co-morbidities [1, 2, 4–6]
*Cholangiocarcinoma, endometrial adenocarcinoma, malignant melanoma, 
metastatic breast cancer, metastatic parathyroid carcinoma with primary 
hyperparathyroidism, multiple myeloma and chronic myelocytic leukaemia.
†Systemic lupus erythematosus, rheumatoid arthritis, giant cell arteritis, 
sarcoidosis and Crohn’s disease.
‡Protein C and S deficiency, antithrombin III deficiency, cryofibrinogenemia and 
antiphospholipid antibody syndrome.
§Cyclophosphamide, adriamycin and fluorouracil.
Table 2. Differential diagnoses of non-uremic calciphylaxis [1]
Non-uremic chronic kidney disease
PTH abnormalities (chronic hyper- and hypoparathyroidism)
Vitamin D abnormalities
Osteoporosis and other conditions with bone mineral loss
Malignancy (solid and haematological)*
Autoimmune and granulomatous diseases†
Other chronic inflammation states
Alcoholic and other chronic liver diseases
Prothrombotic conditions‡
Diabetes mellitus
Aluminium toxicity
Drugs
          - Corticosteroid therapy
          - Warfarin
          - Chemoteraphy§
Infection
Obesity
Rapid weight loss
Female gender
Atherosclerotic vascular disease
Cholesterol embolization
Nephrogenic systemic fibrosis
Oxalate vasculopathy
Purpura fulminans
Vasculitis
Warfarin necrosis
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CASE DESCRIPTION
We present the case of a 78-year-old female patient with a known clinical history of obesity, arterial hypertension, diabetes mellitus (DM), 
dyslipidaemia, heart failure, atrial fibrillation, cardio-embolic stroke with left hemiparesis, chronic venous insufficiency and rheumatoid 
arthritis. Chronic medication included isophane insulin, metformin, digoxin, warfarin, ramipril, amlodipine, rosuvastatin, pantoprazole, 
prednisone and folic acid. Over a period of 8 weeks, the patient developed painful cutaneous ulcers initially on the right thigh, and later on 
both legs, characterized by irregular stellate borders, purpuric edges, and dry necrosis with a black eschar. The patient was hospitalized with 
a diagnosis of sepsis following disease progression and the development of infected ulcers.
Sepsis was treated with empiric antibiotic therapy as blood and wound cultures were sterile. Warfarin was switched to enoxaparin and 
prednisone reduced to 5 mg daily. However, the skin ulcers remained resistant to wound care and new lesions appeared. Smaller violaceous 
non-ulcerated plaques and mottled to reticular purpura of surrounding skin were also present (Fig. 1). Therefore, a cutaneous punch biopsy 
on the edge of a skin ulcer was performed.
On histopathological examination, arteriole calcium deposition, thrombosis and panniculitis were observed (Fig. 2). These findings were 
diagnostic for calciphylaxis. The complementary investigation demonstrated a normal kidney function, normal levels of serum calcium, 
phosphorus, vitamin D and parathormone, an immune profile compatible with rheumatoid arthritis, a normal coagulation study, an arterial 
Doppler without flow disturbances, and a lower limb x-ray showing a calcified arterial net.
In light of the diagnosis of calciphylaxis, wound care was maintained with regular debridement, appropriate dressings and infection control, 
along with opioids for analgesia. A single session of HOT was performed, with poor patient tolerability. Treatment with STS was considered, 
but the patient died from septic shock 12 weeks after admission. 
Figure 1. Painful stellate necrotic ulcers with mottled to 
reticular purpura of surrounding skin on both legs and 
the right thigh (a, b, d); reticular violaceous stellate non-
ulcerated plaque on the left thigh (c)
Figure 2. Histology of cutaneous biopsy, with haematoxylin-
eosin (a, ×100) and von Kossa (b, ×40) staining. There is 
calcification and occlusion of small arteries in subcutis, 
thickened adipose septa and extensive calcium deposition—
findings consistent with the diagnosis of calciphylaxis
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DISCUSSION
NUC usually presents clinically with characteristic painful non-healing skin ulcers on the lower limbs, in the absence of ESKD, although 
there are some clinical differential diagnoses (Table 2). The definite diagnosis of calciphylaxis was established by the pathognomonic 
histopathological characteristics of a sample obtained through punch biopsy. The collaboration between multiple specialties, mainly Internal 
Medicine and Dermatology, a high level of suspicion and a good quality tissue sample for histopathological examination were fundamental 
for making the diagnosis in our patient.
In this case, female gender, obesity, DM, rheumatoid arthritis, and chronic warfarin and prednisone therapies may be have been possible 
triggers for NUC. 
The management of this patient was insufficient to avoid death from sepsis, a common clinical course in reports of NUC. This disease 
represents a diagnostic and therapeutic challenge, with treatment currently limited to debridement, analgesia, and control of triggers 
and septic complications. Some therapeutic alternatives are mentioned in the literature, but mortality remains high and more efficient 
therapeutic measures and evidence-based recommendations are needed. 
